PubMed Health⌕ Search

Biomedical subjects

M F Heyworth

Publications and source records attributed to M F Heyworth.

46 records · Page 3Linked to original sources
PubMed1981

Effects of anti-lymphocytic globulin in human subjects.

Some of the immunological effects of anti-lymphocytic globulin (ALG) were examined in patients taking part in a clinical study of equine ALG in ulcerative colitis. ALG administration led to reduction in the percentage of peripheral blood lymphocytes forming spontaneous rosettes with sheep erythrocytes (E rosettes). Evidence was obtained that this reduction was the result of genuine depletion of circulating T (thymus-dependent) lymphocytes, rather than blockade of E-rosette formation by ALG on lymphocyte surfaces. Using an immunofluorescence technique, horse Ig was demonstrated on lymphocytes from patients receiving ALG. By combining this technique with E-rosette formation, horse Ig was detected on patients' E-rosette-positive and -negative lymphocytes. Horse Ig levels in patients' sera were measured by haemagglutination inhibition, and the sera were also examined for anti-lymphocytic antibodies. Although lymphocyte-binding horse Ig was detectable in teh patients' sera, lymphocytotoxic antibody could not be demonstrated. It can be concluded that lymphocytotoxic antibody was rapidly removed from the serum of patients receiving ALG, by binding to circulating lymphocytes.

Antibody Formation↗
PubMed1980

A therapeutic trial of anti-lymphocytic globulin in acute ulcerative colitis.

The results of the preliminary part of a controlled therapeutic trial of antilymphocytic globulin (ALG) in severe acute ulcerative colitis are presented. 10 patients have been studied in this part of the trial, 5 receiving standard treatment with corticosteroids, and 5 receiving ALG, in a dose of 1 g daily for 5 days, in addition to the standard treatment. No difference has been observed in the clinical course of the patients in the two groups. A continuation of the trial is in progress, using ALG in a larger dose (2 g daily for 5 days).

Acute Disease↗
PubMed1980

Influence of two different fixatives on the identification of plasma cells in human rectal mucosa.

Plasma cells in sections of bisected human rectal biopsy specimens, fixed in two alternative fixatives, were enumerated after staining by an indirect immunoperoxidase procedure intended to demonstrate immunoglobulin-containing cells. The counts of immunoperoxidase-positive plasma cells were significantly higher after fixation in formol sublimate than after fixation in formol saline. Formol sublimate appears to be a more reliable fixative than formol saline for specimens of rectal mucosa in which quantitation of plasma cells, stained for intracellular immunoglobulin by an immunoperoxidase technique, is intended.

Biopsy↗
PubMed1979

Comparison of disodium cromoglycate and sulphasalazine as maintenance therapy for ulcerative colitis.

In a trial lasting six months disodium cromoglycate (800 mg daily), sulphasalazine (2 g daily), and these two agents in combination were compared in 120 patients as maintenance treatment for ulcerative colitis. Relapse was defined as recurrence of colitic symptoms accompanied by sigmoidoscopic evidence of inflammation. The patients receiving disodium cromoglycate had a much higher relapse-rate than those taking sulphasalazine and the results with the two agents combined were little different from those with sulphasalazine alone. Disodium cromoglycate in the dose employed is greatly inferior to sulphasalazine as maintenance treatment for the prevention of relapse in ulcerative colitis.

Administration, Oral↗
PubMed1975

Glomerulonephritis associated with Coxiella burnetii endocarditis.

A patient with endocarditis associated with chronic Coxiella burnetii infection is described in whom glomerulonephritis developed with granular deposits containing immunoglobulins and complement in the glomeruli. The serum was notable for the variety of circulating antibodies detected, which included antibodies directed against native DNA.

Adult↗
PubMed1974

Nephrotic syndrome in chronic lymphocytic leukaemia.

Two patients with chronic lymphocytic leukaemia and the nephrotic syndrome are described in whom deposits were shown in renal glomerular basement membranes in a pattern suggesting immune-complex glomerulonephritis. This renal lesion has been described in one case of squamous carcinoma of the bronchus, in one case of Burkitt's lymphoma, and in three cases of Hodgkin's disease though not previously in chronic lymphocytic leukaemia. Immune-complex glomerulonephritis is, however, a recognized finding in mice infected with leukaemogenic viruses

Aged↗
PubMedDate not supplied

Cytotoxic effect of anti-lymphocytic globulin on human lymphoid cells.

The cytotoxic activity of two anti-lymphocytic globulin (ALG) preparations was investigated by measurement of 51Cr release from human peripheral blood mononuclear cells and tonsil lymphocytes incubated with ALG in the presence of complement. Both types of ALG had a greater complement-dependent cytotoxic effect on tonsil lymphocytes than on peripheral blood mononuclear cells. The ALG preparations were more cytotoxic for a population of tonsil lymphocytes enriched in non-T cells than for one enriched in T cells. This finding does not support the view that ALG has a selective action on T lymphocytes.

Antilymphocyte Serum↗
PubMedDate not supplied

Problems associated with the use of merthiolate as a preservative in anti-lymphocytic globulin.

The cytotoxic properties of 2 anti-lymphocytic globulin (ALG) preparations were investigated in vitro by measuring the release of 51Cr from labelled human peripheral blood mononuclear cells, tonsil lymphocytes and Chang cells, incubated with different concentrations of ALG. One of the ALG preparations showed non-selective cytotoxicity in the absence of complement. Evidence was obtained to suggest that this effect was due to merthiolate (sodium ethylmercurithiosalicylate) which had been added to the ALG as a preservative during manufacture. The mercury concentration in the ALG was found to be greater than that stated by the manufacturers. It is conceivable that the clinical use of such as ALG preparation might lead to mercury accumulation in the tissues, with resulting toxic effects. The whole question of the use of merthiolate in the preparation of sera for administration to human subjects needs to be reconsidered.

Antilymphocyte Serum↗